Cancer Stem Cells Market By Cancer Forms, By Application : Global Opportunity Analysis and Industry Forecast, 2021-2031

List of Tables

The global cancer stem cells market is envisioned to garner $2,711.8 million by 2031, growing from $1,055.2 million in 2021 at a CAGR of 10.0% from 2022 to 2031.

Cancers are time-related illnesses that pose a major threat to human life. For the treatment of cancer, a variety of methods have been developed, including surgery, chemo, radiation, and targeted therapy. Because of all these treatments, the incidence rate of cancer has been steady in women and has somewhat decreased in males, and the death rate from cancer has also decreased over the same period. Traditional cancer treatments, which only work for certain types of malignant tumors, metastasis, heterogeneity, as well as resistance to chemotherapy, radiotherapy, and avoiding immunological surveillance are the primary causes of cancer treatment failures. The traits of cancer stem cells could be the cause of all these failures. Due to their capacity to stop in the early phase, which results in the formation of fresh tumors, cancer stem cells can lead to cancer spread, cancer relapse, multidrug resistance, and radiation resistance. Cancer stem cells may therefore be considered of as the most promising cancer effective treatments.

The clinical procedures involved in stem cell transplantation are complex and high risk, including radiation therapy that is used to diagnose malignancy. Cancer stem cells (CSCs) and regular stem cells share many fundamental biologicals signaling pathways. Normal stem cells may become CSCs when their microenvironment changes negatively, which then causes the creation of the complete tumor tissue. While in culture prior to transplantation, transplanted stem cells may be exposed to environmental factors that could alter their genomic expression and future phenotype. Stem cells are more likely to become cancerous cells with increased culture time. These factors are predicted to hamper the cancer stem cells market growth in forecast time period.

Cancer stem cells are one of the causes of cancer cell relapse and metastasis. They are resistant to the majority of chemotherapeutic treatments. Additionally, cancer stem cell contributes to tumor cell heterogeneity and recurrent illness to some extent. Cancer stem cells must be addressed if total tumor regression is to be achieved. Recent developments in immunotherapies have demonstrated encouraging results in the treatment of cancer, which are also applicable to cancer stem cells. Cancer stem cells in different tumors express immunological markers and show certain immune traits, which can be exploited in immunotherapies to target cancer stem cells in the tumor microenvironment. Cancer stem cells have recently gained huge traction when it comes to technological advancements as well as research & development (R&D) initiatives. Cancer stem cells are increasingly being targeted using dendritic cell (DC)-based vaccines, adaptive T-cells, oncolytic viruses, immune checkpoint inhibitors, and combination treatments.

The COVID-19 pandemic brought several uncertainties leading to severe economic losses as various businesses across the world were at a standstill. The COVID-19 outbreak caused a significant effect on the cancer stem cell market growth. The rise in cancer cases globally is increasing the need for efficacious cancer stem cell therapies. Cancer stem cell researchers along with various government bodies are massively investing in Research and Development activities for cell-based therapies to cater to the rising demand for cancer cell therapies during the COVID-19 pandemic. For instance, during the COVID-19 pandemic, the use of stem cell applicability for resistance to the COVID-19 pandemic is researched.

The key players profiled in this report include: AdnaGen GmbH, Advanced Cell Diagnostics, Inc., AVIVA Biosciences Corporation, Celula, Inc., Epic Sciences, Inc., Fluxion Biosciences, Inc., Rarecells USA, Inc. and Silicon Biosystems, S.p.A.

Key Market Segments

By Cancer Forms

Breast
Blood
Lung
Brain
Colorectal
Pancreatic
Bladder
Liver
Others

By Application

Trageted Cancerous Stem Cells
Stem Cell-based cancer Therapy

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest Of Asia Pacific
LAMEA
- Brazil
- Saudi Arabia
- UAE
- South Africa
- Rest of LAMEA
Key Market Players
- Thermo Fisher Scientific Inc.
- AbbVie Inc.
- Miltenyi Biotec
- STEMCELL Technologies Inc.
- Merck KGaA
- Stemline Therapeutics, Inc.
- MacroGenics, Inc.
- Bionomics
- FUJIFILM Irvine Scientific.
- Lineage Cell Therapeutics, Inc.

Product Code: A08105

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings
- 3.2.1.Top investment pockets
3.3.Porter's five forces analysis
3.4.Top player positioning
3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
3.7.Regulatory Guidelines
3.8.Value Chain Analysis
3.9.Market Share Analysis
3.10.Key Regulation Analysis
3.11.Patent Landscape

CHAPTER 4: CANCER STEM CELLS MARKET, BY CANCER FORMS

4.1 Overview
- 4.1.1 Market size and forecast
4.2 Breast
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
4.3 Blood
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
4.4 Lung
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market analysis by country
4.5 Brain
- 4.5.1 Key market trends, growth factors and opportunities
- 4.5.2 Market size and forecast, by region
- 4.5.3 Market analysis by country
4.6 Colorectal
- 4.6.1 Key market trends, growth factors and opportunities
- 4.6.2 Market size and forecast, by region
- 4.6.3 Market analysis by country
4.7 Pancreatic
- 4.7.1 Key market trends, growth factors and opportunities
- 4.7.2 Market size and forecast, by region
- 4.7.3 Market analysis by country
4.8 Bladder
- 4.8.1 Key market trends, growth factors and opportunities
- 4.8.2 Market size and forecast, by region
- 4.8.3 Market analysis by country
4.9 Liver
- 4.9.1 Key market trends, growth factors and opportunities
- 4.9.2 Market size and forecast, by region
- 4.9.3 Market analysis by country
5.0 Others
- 5.0.1 Key market trends, growth factors and opportunities
- 5.0.2 Market size and forecast, by region
- 5.0.3 Market analysis by country

CHAPTER 5: CANCER STEM CELLS MARKET, BY APPLICATION

5.1 Overview
- 5.1.1 Market size and forecast
5.2 Trageted Cancerous Stem Cells
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
5.3 Stem Cell-based cancer Therapy
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country

CHAPTER 6: CANCER STEM CELLS MARKET, BY REGION

6.1 Overview
- 6.1.1 Market size and forecast
6.2 North America
- 6.2.1 Key trends and opportunities
- 6.2.2 North America Market size and forecast, by Cancer Forms
- 6.2.3 North America Market size and forecast, by Application
- 6.2.4 North America Market size and forecast, by country
  - 6.2.4.1 U.S.
  - 6.2.4.1.1 Market size and forecast, by Cancer Forms
  - 6.2.4.1.2 Market size and forecast, by Application
  - 6.2.4.2 Canada
  - 6.2.4.2.1 Market size and forecast, by Cancer Forms
  - 6.2.4.2.2 Market size and forecast, by Application
  - 6.2.4.3 Mexico
  - 6.2.4.3.1 Market size and forecast, by Cancer Forms
  - 6.2.4.3.2 Market size and forecast, by Application
6.3 Europe
- 6.3.1 Key trends and opportunities
- 6.3.2 Europe Market size and forecast, by Cancer Forms
- 6.3.3 Europe Market size and forecast, by Application
- 6.3.4 Europe Market size and forecast, by country
  - 6.3.4.1 Germany
  - 6.3.4.1.1 Market size and forecast, by Cancer Forms
  - 6.3.4.1.2 Market size and forecast, by Application
  - 6.3.4.2 United Kingdom
  - 6.3.4.2.1 Market size and forecast, by Cancer Forms
  - 6.3.4.2.2 Market size and forecast, by Application
  - 6.3.4.3 France
  - 6.3.4.3.1 Market size and forecast, by Cancer Forms
  - 6.3.4.3.2 Market size and forecast, by Application
  - 6.3.4.4 Spain
  - 6.3.4.4.1 Market size and forecast, by Cancer Forms
  - 6.3.4.4.2 Market size and forecast, by Application
  - 6.3.4.5 Italy
  - 6.3.4.5.1 Market size and forecast, by Cancer Forms
  - 6.3.4.5.2 Market size and forecast, by Application
  - 6.3.4.6 Rest of Europe
  - 6.3.4.6.1 Market size and forecast, by Cancer Forms
  - 6.3.4.6.2 Market size and forecast, by Application
6.4 Asia-Pacific
- 6.4.1 Key trends and opportunities
- 6.4.2 Asia-Pacific Market size and forecast, by Cancer Forms
- 6.4.3 Asia-Pacific Market size and forecast, by Application
- 6.4.4 Asia-Pacific Market size and forecast, by country
  - 6.4.4.1 China
  - 6.4.4.1.1 Market size and forecast, by Cancer Forms
  - 6.4.4.1.2 Market size and forecast, by Application
  - 6.4.4.2 Japan
  - 6.4.4.2.1 Market size and forecast, by Cancer Forms
  - 6.4.4.2.2 Market size and forecast, by Application
  - 6.4.4.3 India
  - 6.4.4.3.1 Market size and forecast, by Cancer Forms
  - 6.4.4.3.2 Market size and forecast, by Application
  - 6.4.4.4 South Korea
  - 6.4.4.4.1 Market size and forecast, by Cancer Forms
  - 6.4.4.4.2 Market size and forecast, by Application
  - 6.4.4.5 Australia
  - 6.4.4.5.1 Market size and forecast, by Cancer Forms
  - 6.4.4.5.2 Market size and forecast, by Application
  - 6.4.4.6 Rest Of Asia Pacific
  - 6.4.4.6.1 Market size and forecast, by Cancer Forms
  - 6.4.4.6.2 Market size and forecast, by Application
6.5 LAMEA
- 6.5.1 Key trends and opportunities
- 6.5.2 LAMEA Market size and forecast, by Cancer Forms
- 6.5.3 LAMEA Market size and forecast, by Application
- 6.5.4 LAMEA Market size and forecast, by country
  - 6.5.4.1 Brazil
  - 6.5.4.1.1 Market size and forecast, by Cancer Forms
  - 6.5.4.1.2 Market size and forecast, by Application
  - 6.5.4.2 Saudi Arabia
  - 6.5.4.2.1 Market size and forecast, by Cancer Forms
  - 6.5.4.2.2 Market size and forecast, by Application
  - 6.5.4.3 UAE
  - 6.5.4.3.1 Market size and forecast, by Cancer Forms
  - 6.5.4.3.2 Market size and forecast, by Application
  - 6.5.4.4 South Africa
  - 6.5.4.4.1 Market size and forecast, by Cancer Forms
  - 6.5.4.4.2 Market size and forecast, by Application
  - 6.5.4.5 Rest of LAMEA
  - 6.5.4.5.1 Market size and forecast, by Cancer Forms
  - 6.5.4.5.2 Market size and forecast, by Application

CHAPTER 7: COMPANY LANDSCAPE

7.1. Introduction
7.2. Top winning strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Key developments

CHAPTER 8: COMPANY PROFILES

8.1 Thermo Fisher Scientific Inc.
- 8.1.1 Company overview
- 8.1.2 Company snapshot
- 8.1.3 Operating business segments
- 8.1.4 Product portfolio
- 8.1.5 Business performance
- 8.1.6 Key strategic moves and developments
8.2 AbbVie Inc.
- 8.2.1 Company overview
- 8.2.2 Company snapshot
- 8.2.3 Operating business segments
- 8.2.4 Product portfolio
- 8.2.5 Business performance
- 8.2.6 Key strategic moves and developments
8.3 Miltenyi Biotec
- 8.3.1 Company overview
- 8.3.2 Company snapshot
- 8.3.3 Operating business segments
- 8.3.4 Product portfolio
- 8.3.5 Business performance
- 8.3.6 Key strategic moves and developments
8.4 STEMCELL Technologies Inc.
- 8.4.1 Company overview
- 8.4.2 Company snapshot
- 8.4.3 Operating business segments
- 8.4.4 Product portfolio
- 8.4.5 Business performance
- 8.4.6 Key strategic moves and developments
8.5 Merck KGaA
- 8.5.1 Company overview
- 8.5.2 Company snapshot
- 8.5.3 Operating business segments
- 8.5.4 Product portfolio
- 8.5.5 Business performance
- 8.5.6 Key strategic moves and developments
8.6 Stemline Therapeutics, Inc.
- 8.6.1 Company overview
- 8.6.2 Company snapshot
- 8.6.3 Operating business segments
- 8.6.4 Product portfolio
- 8.6.5 Business performance
- 8.6.6 Key strategic moves and developments
8.7 MacroGenics, Inc.
- 8.7.1 Company overview
- 8.7.2 Company snapshot
- 8.7.3 Operating business segments
- 8.7.4 Product portfolio
- 8.7.5 Business performance
- 8.7.6 Key strategic moves and developments
8.8 Bionomics
- 8.8.1 Company overview
- 8.8.2 Company snapshot
- 8.8.3 Operating business segments
- 8.8.4 Product portfolio
- 8.8.5 Business performance
- 8.8.6 Key strategic moves and developments
8.9 FUJIFILM Irvine Scientific.
- 8.9.1 Company overview
- 8.9.2 Company snapshot
- 8.9.3 Operating business segments
- 8.9.4 Product portfolio
- 8.9.5 Business performance
- 8.9.6 Key strategic moves and developments
8.10 Lineage Cell Therapeutics, Inc.
- 8.10.1 Company overview
- 8.10.2 Company snapshot
- 8.10.3 Operating business segments
- 8.10.4 Product portfolio
- 8.10.5 Business performance
- 8.10.6 Key strategic moves and developments